Clinical Study
Sustained Release Formulation of Primaquine for Prevention of Relapse of Plasmodium vivax Malaria: A Randomized, Double-Blind, Comparative, Multicentric Study
Table 4
Numbers of AEs reported during chloroquine therapy and primaquine therapy.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
P 15 mg: conventional primaquine 15 mg, PSR 15 mg: primaquine sustained release 15 mg, and PSR 30 mg: primaquine sustained release 30 mg. value: P 15 mg versus PSR 15 mg (), P 15 mg versus PSR 30 mg (), and PSR 15 mg versus PSR 30 mg () (for patients reporting adverse events). |